Figure 7.
(A) The strategy to structural modification of the MDM2 ligand; (B) Cell viability assay for indicated compounds; (C) Immunoblot of MDM2, p53, and GSPT1 following treatment of cells with DMSO or indicated compounds for 6 h.
Official websites use .gov
A
.gov website belongs to an official
government organization in the United States.
Secure .gov websites use HTTPS
A lock (
) or https:// means you've safely
connected to the .gov website. Share sensitive
information only on official, secure websites.